GPX4 and myelodysplastic syndrome: Decitabine, a key therapeutic agent for high-risk MDS, has been shown to elevate ROS levels within the bone marrow cells of MDS patients by down-regulating GSH and GPX4 levels, which subsequently leads to ferroptosis.